An update on the pathogenic role of IL-6 in rheumatic diseases.

Abstract

Interleukin (IL)-6 is a pleiotropic cytokine that is involved in the pathogenesis of various rheumatic diseases. Direct inhibition of the IL-6 pathway by an anti-IL-6 receptor or inhibiting the ligand itself has proved to be efficacious in the treatment of these diseases. Juvenile idiopathic arthritis, adult-onset Still's disease, large vessel vasculitis including giant cell arteritis and Takayasu disease, systemic sclerosis, and polymyalgia rheumatica respond well to IL-6 inhibition as expected. However, no clinically meaningful effect has been observed with regard to IL-6 blockade in ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. This review discusses the current state of IL-6 targeting approaches in various rheumatic diseases other than rheumatoid arthritis.

• Authors: Yuko Kaneko, Tsutomu Takeuchi
• Journal: Cytokine (Cytokine) Vol. 146 Pg. 155645 (10 2021) ISSN: 1096-0023 [Electronic] England
• PMID: 34303949 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• Interleukin-6

Topics

• Animals
• COVID-19 (pathology)
• Humans
• Interleukin-6 (antagonists & inhibitors, metabolism)
• Randomized Controlled Trials as Topic
• Rheumatic Diseases (etiology)
• Treatment Outcome